369 related articles for article (PubMed ID: 26567753)
1. Targeting HER 2 and angiogenesis in gastric cancer.
Jomrich G; Schoppmann SF
Expert Rev Anticancer Ther; 2016; 16(1):111-22. PubMed ID: 26567753
[TBL] [Abstract][Full Text] [Related]
2. Ramucirumab: successfully targeting angiogenesis in gastric cancer.
Javle M; Smyth EC; Chau I
Clin Cancer Res; 2014 Dec; 20(23):5875-81. PubMed ID: 25281695
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis inhibitors in early development for gastric cancer.
Pinto MP; Owen GI; Retamal I; Garrido M
Expert Opin Investig Drugs; 2017 Sep; 26(9):1007-1017. PubMed ID: 28770623
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight.
Aprile G; Ongaro E; Del Re M; Lutrino SE; Bonotto M; Ferrari L; Rihawi K; Cardellino GG; Pella N; Danesi R; Fasola G
Crit Rev Oncol Hematol; 2015 Aug; 95(2):165-78. PubMed ID: 25800976
[TBL] [Abstract][Full Text] [Related]
5. Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.
Papa A; Zaccarelli E; Caruso D; Vici P; Benedetti Panici P; Tomao F
Expert Opin Investig Drugs; 2016; 25(1):31-49. PubMed ID: 26560489
[TBL] [Abstract][Full Text] [Related]
6. Current advances in targeted therapies for metastatic gastric cancer: improving patient care.
Aguiar PN; Muniz TP; Miranda RR; Tadokoro H; Forones NM; Monteiro ID; Castelo-Branco P; Janjigian YY; De Mello RA
Future Oncol; 2016 Mar; 12(6):839-54. PubMed ID: 26838766
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis and apatinib: a new hope for patients with advanced gastric cancer?
de Mello RA; de Oliveira J; Antoniou G
Future Oncol; 2017 Feb; 13(4):295-298. PubMed ID: 27928929
[No Abstract] [Full Text] [Related]
8. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials.
Shan F; Miao R; Xue K; Li Z; Li Z; Bu Z; Wu A; Zhang L; Wu X; Zong X; Wang X; Li S; Ji X; Jia Z; Li Z; Ji J
Cancer Lett; 2016 Oct; 380(2):598-607. PubMed ID: 26724681
[TBL] [Abstract][Full Text] [Related]
9. Gastric Carcinoma at the Era of Targeted Therapies.
Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis in Colorectal Cancer: Antibodies.
Chan E
Cancer J; 2016; 22(3):179-81. PubMed ID: 27341595
[TBL] [Abstract][Full Text] [Related]
11. Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
Tehfe M; Tabchi S; Laterza MM; De Vita F
Future Oncol; 2018 Feb; 14(3):223-228. PubMed ID: 29318901
[TBL] [Abstract][Full Text] [Related]
12. Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety.
Narita Y; Muro K
Expert Opin Drug Saf; 2017 Mar; 16(3):319-327. PubMed ID: 27976952
[TBL] [Abstract][Full Text] [Related]
13. Current and Future Therapies for Advanced Gastric Cancer.
Davidson M; Okines AF; Starling N
Clin Colorectal Cancer; 2015 Dec; 14(4):239-50. PubMed ID: 26524924
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic therapies for gastric cancer.
Hironaka S
Asia Pac J Clin Oncol; 2019 Aug; 15(4):208-217. PubMed ID: 31111678
[TBL] [Abstract][Full Text] [Related]
15. How Can Gastric Cancer Molecular Profiling Guide Future Therapies?
Corso S; Giordano S
Trends Mol Med; 2016 Jul; 22(7):534-544. PubMed ID: 27260398
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.
Aprile G; Ferrari L; Cremolini C; Bergamo F; Fontanella C; Battaglin F; Rihawi K; Lonardi S; Loupakis F; Scartozzi M
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):877-85. PubMed ID: 27149032
[TBL] [Abstract][Full Text] [Related]
17. HER2-targeted therapies in gastric cancer.
Zhu Y; Zhu X; Wei X; Tang C; Zhang W
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188549. PubMed ID: 33894300
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.
Roviello G; Petrioli R; Marano L; Polom K; Marrelli D; Perrella A; Roviello F
Gastric Cancer; 2016 Jan; 19(1):31-41. PubMed ID: 26329368
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy for gastric cancer: Current status and future directions (Review).
Yuan DD; Zhu ZX; Zhang X; Liu J
Oncol Rep; 2016 Mar; 35(3):1245-54. PubMed ID: 26718131
[TBL] [Abstract][Full Text] [Related]
20. A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition.
Labanca V; Bertolini F
EBioMedicine; 2016 Aug; 10():13-4. PubMed ID: 27506898
[No Abstract] [Full Text] [Related]
[Next] [New Search]
